Michael A.  Zasloff net worth and biography

Michael Zasloff Biography and Net Worth

Michael A. Zasloff, M.D., Ph.D. has served as a member of our Board of Directors since October 2005. Dr. Zasloff has been the Professor of Surgery and Pediatrics at the Georgetown University School of Medicine since January 2002, and was also the Dean of Research and Translational Science from January 2002 until July 2004. Between July 2004 and 2007, Dr. Zasloff served as Vice President and Senior Analyst (Life Sciences) at Ferris, Baker Watts, Inc.  From 1992 to 2001 he served as Executive Vice President and Vice Chairman of Magainin Pharmaceuticals Inc., a publicly-held biopharmaceutical company which he founded, with research and development efforts in anti-angiogenesis, respiratory genomics and infectious disease.   From 1988 until 1992, Dr. Zasloff served as the Charles E.H. Upham Professor, Department of Pediatrics and Genetics, University of Pennsylvania School of Medicine, and Chief, Division of Human Genetics and Molecular Biology at The Children's Hospital of Philadelphia. From 1982 until 1988, he was Chief, Human Genetics Branch, National Institutes of Child Health and Human Development, National Institutes of Health. Dr. Zasloff received a B.A. from Columbia College in Chemistry and holds an M.D., Ph.D. from the New York University School of Medicine. He is named the inventor on over 40 patents, has been widely published in scholarly journals, and has been the recipient of numerous awards.

What is Michael A. Zasloff's net worth?

The estimated net worth of Michael A. Zasloff is at least $949,646.78 as of March 5th, 2024. Dr. Zasloff owns 21,326 shares of Amphastar Pharmaceuticals stock worth more than $949,647 as of March 28th. This net worth evaluation does not reflect any other investments that Dr. Zasloff may own. Learn More about Michael A. Zasloff's net worth.

How do I contact Michael A. Zasloff?

The corporate mailing address for Dr. Zasloff and other Amphastar Pharmaceuticals executives is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. Amphastar Pharmaceuticals can also be reached via phone at (909) 980-9484 and via email at [email protected]. Learn More on Michael A. Zasloff's contact information.

Has Michael A. Zasloff been buying or selling shares of Amphastar Pharmaceuticals?

Within the last three months, Michael A. Zasloff has sold $589,750.00 in Amphastar Pharmaceuticals stock. Most recently, Michael A. Zasloff sold 12,500 shares of the business's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $47.18, for a transaction totalling $589,750.00. Following the completion of the sale, the director now directly owns 21,326 shares of the company's stock, valued at $1,006,160.68. Learn More on Michael A. Zasloff's trading history.

Who are Amphastar Pharmaceuticals' active insiders?

Amphastar Pharmaceuticals' insider roster includes Diane Gerst (Director), Richard Koo (Director), Howard Lee (Director), Yakob Liawatidewi (EVP), Mary Luo (COO), Ziping Luo (Chairman), William Peters (CFO), Floyd Petersen (Director), Richard Prins (Director), Michael Zasloff (Director), Jack Zhang (CEO), Yongfeng Zhang (Co-Founder), and Rong Zhou (EVP). Learn More on Amphastar Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Amphastar Pharmaceuticals?

In the last year, insiders at the sold shares 33 times. They sold a total of 551,742 shares worth more than $29,081,251.11. The most recent insider tranaction occured on March, 5th when Director Michael A Zasloff sold 12,500 shares worth more than $589,750.00. Insiders at Amphastar Pharmaceuticals own 28.4% of the company. Learn More about insider trades at Amphastar Pharmaceuticals.

Information on this page was last updated on 3/5/2024.

Michael A. Zasloff Insider Trading History at Amphastar Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/5/2024Sell12,500$47.18$589,750.0021,326View SEC Filing Icon  
8/15/2023Sell12,759$57.22$730,069.9833,826View SEC Filing Icon  
5/15/2023Sell7,500$42.18$316,350.0043,869View SEC Filing Icon  
5/16/2022Sell10,291$35.61$366,462.5147,206View SEC Filing Icon  
3/16/2022Sell10,000$33.71$337,100.00View SEC Filing Icon  
5/13/2021Sell25,827$19.34$499,494.1867,014View SEC Filing Icon  
5/14/2020Sell14,832$18.00$266,976.0050,168View SEC Filing Icon  
5/12/2020Sell10,000$19.00$190,000.0045,336View SEC Filing Icon  
6/12/2018Sell15,000$16.52$247,800.0029,845View SEC Filing Icon  
10/2/2017Sell63,624$18.18$1,156,684.32101,879View SEC Filing Icon  
6/1/2017Sell15,000$17.01$255,150.0047,411View SEC Filing Icon  
8/15/2016Sell48,375$18.15$878,006.2542,792View SEC Filing Icon  
7/17/2015Sell7,692$17.41$133,917.72View SEC Filing Icon  
8/19/2014Buy3,500$10.00$35,000.00View SEC Filing Icon  
See Full Table

Michael A. Zasloff Buying and Selling Activity at Amphastar Pharmaceuticals

This chart shows Michael A Zasloff's buying and selling at Amphastar Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amphastar Pharmaceuticals Company Overview

Amphastar Pharmaceuticals logo
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Read More

Today's Range

Now: $43.91
Low: $43.76
High: $44.83

50 Day Range

MA: $50.15
Low: $42.85
High: $56.02

2 Week Range

Now: $43.91
Low: $35.62
High: $67.66

Volume

453,245 shs

Average Volume

490,540 shs

Market Capitalization

$2.11 billion

P/E Ratio

17.02

Dividend Yield

N/A

Beta

0.85